Careers  |   Log In  |   Register  |   Welcome Center  |   Follow Us  Facebook  Twitter Google Plus

Latest in Hematology-Oncology

Reuters Health • The Doctor's Channel Daily Newscast

Romidepsin effective for refractory peripheral T-cell lymphoma

NEW YORK (Reuters Health) – About one in four patients with peripheral T-cell lymphoma (PTCL) who do not respond to or relapse after systemic therapy are likely to have an objective response to romidepsin, a potent histone deacetylase inhibitor,...

Reuters Health • The Doctor's Channel Daily Newscast

Benefit of rituximab-EPOCH for HIV-related lymphoma confirmed

NEW YORK (Reuters Health) – A pooled analysis of two trials indicates that HIV patients with aggressive B-cell non-Hodgkin lymphoma (NHL) fare better with a regimen of rituximab combined with EPOCH chemotherapy than rituximab plus CHOP...

Reuters Health • The Doctor's Channel Daily Newscast

CNS prophylaxis for diffuse large cell no longer needed

NEW YORK (Reuters Health) – In the rituximab era, it’s not necessary to administer prophylaxis against central nervous system (CNS) disease in patients with diffuse large B-cell lymphoma (DLBCL), according to “real world” data from a large...